Skip to main content

Advertisement

Log in

Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Since their introduction, statin (HMG-CoA reductase inhibitor) drugs have advanced the practice of cardiology to unparalleled levels. Even so, coronary heart disease (CHD) still remains the leading cause of death in developed countries, and is predicted to soon dominate the causes of global mortality and disability as well. The currently available non-statin drugs have had limited success in reversing the burden of heart disease, but new information suggests they have roles in sizeable subpopulations of those affected. In this review, the status of approved non-statin drugs and the significant potential of newer drugs are discussed. Several different ways to raise plasma high-density lipoprotein (HDL) cholesterol (HDL-C) levels have been proposed, but disappointments are now in large part attributed to a preoccupation with HDL quantity, rather than quality, which is more important in cardiovascular (CV) protection. Niacin, an old drug with many antiatherogenic properties, was re-evaluated in two imperfect randomized controlled trials (RCTs), and failed to demonstrate clear effectiveness or safety. Fibrates, also with an attractive antiatherosclerotic profile and classically used for hypertriglyceridemia, lacks evidence-based proof of efficacy, save for a subgroup of diabetic patients with atherogenic dyslipidemia. Omega-3 fatty acids fall into this category as well, even with an impressive epidemiological evidence base. Omega-3 research has been plagued with methodological difficulties yielding tepid, uncertain, and conflicting results; well-designed studies over longer periods of time are needed. Addition of ezetimibe to statin therapy has now been shown to decrease levels of low-density lipoprotein (LDL) cholesterol (LDL-C), accompanied by a modest decrease in the number of CV events, though without any improvement in CV mortality. Importantly, the latest data provide crucial evidence that LDL lowering is central to the management of CV disease. Of drugs that inhibit cholesteryl ester transfer protein (CETP) tested thus far, two have failed and two remain under investigation and may yet prove to be valuable therapeutic agents. Monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, now in phase III trials, lower LDL-C by over 50 % and are most promising. These drugs offer new ability to lower LDL-C in patients in whom statin drug use is, for one reason or another, limited or insufficient. Mipomersen and lomitapide have been approved for use in patients with familial hypercholesterolemia, a more common disease than appreciated. Anti-inflammatory drugs are finally receiving due attention in trials to elucidate potential clinical usefulness. All told, even though statins remain the standard of care, non-statin drugs are poised to assume a new, vital role in managing dyslipidemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Kones R, Rumana U. Current therapy of dyslipidemia. A new paradigm for statin drug use and the need for additional therapies. Drugs. 2015. doi:10.1007/s40265-015-0428-4.

  2. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(Suppl 2):S49–S73. App. http://www.cvriskcalculator.com/.

  3. Ray KK, Kastelein JJ, Boekholdt SM, Nicholls SJ, Khaw KT, Ballantyne CM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014;35:960–8.

    PubMed  Google Scholar 

  4. Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman MJ, Cuchel M, et al. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013;7:484–525.

    PubMed  Google Scholar 

  5. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707–14.

    CAS  PubMed  Google Scholar 

  6. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation. 2000;102:1893–900.

    CAS  PubMed  Google Scholar 

  7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.

  8. Nicholls SJ, Tuzcu E, Sipahi I, Grasso AW, Schoenhagen P, Hu T, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499–508.

    CAS  PubMed  Google Scholar 

  9. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, et al. Cholesterol efflux and atheroprotection. Advancing the concept of reverse cholesterol transport. Circulation. 2012;125:1905–19.

    PubMed Central  PubMed  Google Scholar 

  10. Rader DJ, deGoma EM. Approach to the patient with extremely low HDL-cholesterol. J Clin Endocrinol Metab. 2012;97:3399–407.

    CAS  PubMed Central  PubMed  Google Scholar 

  11. Oldoni F, Sinke RJ, Kuivenhoven JA. Mendelian disorders of high density lipoprotein metabolism. Circ Res. 2014;114:124–42.

    CAS  PubMed  Google Scholar 

  12. Phillips MC. Molecular mechanisms of cellular cholesterol efflux. J Biol Chem. 2014;289:24020–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  13. Kamanna VS, Kashyap ML. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep. 2000;2:36–46.

    CAS  PubMed  Google Scholar 

  14. Kamanna VS, Ganji SH, Kashyap ML. Recent advances in niacin and lipid metabolism. Curr Opin Lipidol. 2013;24:239–45.

    CAS  PubMed  Google Scholar 

  15. Holzhäuser E, Albrecht C, Zhou Q, Buttler A, Preusch MR, Blessing E, et al. Nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities. J Cardiovasc Pharmacol. 2011;57:447–54.

    PubMed  Google Scholar 

  16. Wu BJ, Yan L, Charlton F, Witting P, Barter PJ, Rye K-A. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol. 2010;30:968–75.

    CAS  PubMed  Google Scholar 

  17. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–55.

    CAS  PubMed  Google Scholar 

  18. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, the AIM-HIGH Investigators, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67.

    PubMed  Google Scholar 

  19. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laropiprant: trial design, prespecified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279–91.

    PubMed Central  Google Scholar 

  20. The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–312.

    Google Scholar 

  21. Landmesser U. The difficult search for a ‘partner’ of statins in lipid-targeted prevention of vascular events: the re-emergence and fall of niacin. Eur Heart J. 2013;34:1254–7.

    PubMed  Google Scholar 

  22. Lloyd-Jones D. Niacin and HDL cholesterol—time to face facts. N Engl J Med. 2014;371:271–3.

    CAS  PubMed  Google Scholar 

  23. Olbetam (acipimox). http://www.netdoctor.co.uk/heart-and-blood/medicines/olbetam.html. Accessed 24 Sep 2014.

  24. European Medicines Agency, EMA Pharmacovigilance unit. Acipimox only to be used as additional or alternative treatment to reduce high triglyceride levels. Press release 20/12/2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/12/news_detail_002000.jsp&mid=WC0b01ac058004d5c1. Accessed 20 Sep 2014.

  25. Masson D, Jiang XC, Lagrost L, Tall AR. The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J Lipid Res. 2009;50(suppl):S201–6.

    PubMed Central  PubMed  Google Scholar 

  26. Vasan RS, Pencina MJ, Robins SJ, Zachariah JP, Kaur G, D’Agostino RB, et al. Association of circulating cholesteryl ester transfer protein with incidence of cardiovascular disease in the community. Circulation. 2009;120:14–20.

    Google Scholar 

  27. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22.

    CAS  PubMed  Google Scholar 

  28. Barter P, Rye KA. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now? Trends Pharmacol Sci. 2011;32:694–9.

    CAS  PubMed  Google Scholar 

  29. de Haan J, de Vries-van der Weij J, van der Hoorn J. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation. 2008;117:2515–22.

    PubMed  Google Scholar 

  30. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, for the dal-PLAQUE Investigators, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011;378:1547–59.

    CAS  PubMed Central  PubMed  Google Scholar 

  31. Lüscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Münzel T, dal-VESSEL Investigators, et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J. 2012;33:857–65.

    PubMed Central  PubMed  Google Scholar 

  32. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Determining the Efficacy and Tolerability Investigators, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406–15.

    CAS  PubMed  Google Scholar 

  33. University of Oxford. Randomized Evaluation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) study [Clinicaltrials.gov identifier NCT01252953]. Bethesda: US National Institutes of Health. 2011. http://clinicaltrials.gov/show/NCT01252953. Accessed 20 Sep 2014.

  34. Nicholls SJ, Brewer HB, Kastelein JJP, Krueger KA, Wang MD, Shao M, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol. A randomized controlled trial. JAMA. 2011;306:2099–109.

    CAS  PubMed  Google Scholar 

  35. University of Oxford. A study of evacetrapib in high-risk vascular disease (ACCELERATE) [Clinicaltrials.gov identifier NCT01252953]. Bethesda: US National Institutes of Health, 2012 [updated December 19, 2013]. http://clinicaltrials.gov/show/NCT01687998. Accessed 22 Sep 2014.

  36. Rosenson RS, Brewer HB Jr, Ansell B, Barter P, Chapman MJ, Heinecke JW, et al. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation. 2013;128:1256–67.

    PubMed  Google Scholar 

  37. Shao B, Tang C, Sinha A, Mayer PS, Davenport GD, Brot N, et al. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ Res. 2014;114:1733–42.

    CAS  PubMed Central  PubMed  Google Scholar 

  38. Turner S, Voogt J, Davidson M, et al. Measurement of reverse cholesterol transport pathways in humans: in vivo rates of free cholesterol efflux, esterification, and excretion. J Am Heart Assoc. 2012;1:e001826.

    PubMed Central  PubMed  Google Scholar 

  39. Fisher EA, Feig JE, Hewing B, Hazen SL, Smith JD. HDL function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2012;32:2813–20.

    CAS  PubMed Central  PubMed  Google Scholar 

  40. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127–35.

    CAS  PubMed Central  PubMed  Google Scholar 

  41. Spotlight issue on: HDL biology: new insights in metabolism, function, and translation. Table of Contents. Cardiovas Res. 2013;103(3). http://cardiovascres.oxfordjournals.org/content/103/3.toc. Accessed 20 Sep 2014.

  42. Nicholls SJ, Gordon A, Johannson J, Ballantyne CM, Barter PJ, Brewer HB, et al. ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovasc Drugs Ther. 2012;26:181–7.

    CAS  PubMed  Google Scholar 

  43. Tardif JC, Gregoire J, L’Allier PL, Ibrahim R, Lespérance J, Heinonen T, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297:1675–82.

    PubMed  Google Scholar 

  44. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292–300.

    CAS  PubMed  Google Scholar 

  45. Waksman R, Torguson R, Kent K, Pichard A, Suddath W, Satler L, et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol. 2010;55:2727–35.

    PubMed  Google Scholar 

  46. Gille A, Easton R, D’Andrea D, Wright SD, Shear C. CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects. Arterioscler Thromb Vasc Biol. 2014;34:2106–14.

    CAS  PubMed  Google Scholar 

  47. Wood S. HDL mimetic fails to regress plaque in CHI-SQUARE ACS trial, January 3, 2014. Available at http://www.medscape.com/viewarticle/818629. Accessed 21 June 2015.

  48. Neels JG, Grimaldi PA. Physiological functions of peroxisome proliferator-activated receptor β. Physiol Rev. 2014;94:795–858.

    CAS  PubMed  Google Scholar 

  49. Bishop-Bailey D, Wray J. Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. Prostaglandins Other Lipid Mediat. 2003;71:1–22.

    CAS  PubMed  Google Scholar 

  50. Grygiel-Górniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications—a review. Nutrition J. 2014;13:17.

    Google Scholar 

  51. Tenenbaum A, Fisman EZ. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovasc Diabetol. 2012;11:140.

    CAS  PubMed Central  PubMed  Google Scholar 

  52. Torra IP, Chinetti G, Duval C, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr Opin Lipidol. 2001;12:245–54.

    CAS  PubMed  Google Scholar 

  53. Plutzky J. The PPAR-RXR transcriptional complex in the vasculature: energy in the balance. Circ Res. 2011;108:1002–16.

    CAS  PubMed  Google Scholar 

  54. Watts GF, Staels B. Regulation of endothelial nitric oxide synthase by PPAR agonists: molecular and clinical perspectives. Arterioscler Thromb Vasc Biol. 2004;24:619–21.

    CAS  PubMed  Google Scholar 

  55. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237–45.

    CAS  PubMed  Google Scholar 

  56. Tenkanen L, Mänttäri M, Kovanen PT, Virkkunen H, Manninen V. Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med. 2006;166:743–8.

    CAS  PubMed  Google Scholar 

  57. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–8.

    CAS  PubMed  Google Scholar 

  58. The Bezafibrate Infarction Prevention Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102:21–7.

    Google Scholar 

  59. Vakkilainen J, Steiner G, Ansquer JC, Perttunen-Nio H, Taskinen MR. Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes. Diabetes Care. 2002;25:627–8.

    CAS  PubMed  Google Scholar 

  60. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Kim JA, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol. 2005;45:1649–53.

    CAS  PubMed  Google Scholar 

  61. Lim S, Park YM, Sakuma I, Koh KK. How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol. Int J Cardiol. 2013;166:8–14.

    PubMed  Google Scholar 

  62. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol. 2005;95:462–8.

    CAS  PubMed  Google Scholar 

  63. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care. 2002;25:1198–202.

    CAS  PubMed  Google Scholar 

  64. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, FIELD Study Investigators, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–61.

    CAS  PubMed  Google Scholar 

  65. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Effects of combination lipid therapy in type 2 diabetes mellitus, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74.

    PubMed  Google Scholar 

  66. Sirimarco G, Labreuche J, Bruckert E, Goldstein LB, Fox KM, Rothwell PM, on behalf of the PERFORM and SPARCL Investigators and Committees, et al. Stroke. 2014;45:1429–36.

    CAS  PubMed  Google Scholar 

  67. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875–84.

    CAS  PubMed  Google Scholar 

  68. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010;363:692-4; author reply 694-5.

  69. Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis. 2011;217:492–8.

    CAS  PubMed  Google Scholar 

  70. Ballantyne CM, Jones PH, Kelly MT, Setze CM, Lele A, Thakker KM, et al. Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides. Cardiovas Drugs Ther. 2011;25:s59–67.

    Google Scholar 

  71. Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol. 2012;11:125.

    CAS  PubMed Central  PubMed  Google Scholar 

  72. Lincoff A, Tardif J, Schwartz GG, Nicholls SJ, Rydén L, Neal B, AleCardio Investigators, et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio Randomized Clinical Trial. JAMA. 2014;311:1515–25.

    PubMed  Google Scholar 

  73. Goldfine AB, Kaul S, Hiatt WR. Fibrates in the treatment of dyslipidemias—time for a reassessment. N Engl J Med. 2011;365:481–4.

    CAS  PubMed  Google Scholar 

  74. Food and Drug Administration. FDA Drug Safety Communication: review update of Trilipix (fenofibric acid) and the ACCORD Lipid trial. 2011. http://www.fda.gov/Drugs/DrugSafety/ucm278837.htm. Accessed 20 Sep 2014.

  75. Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM. Use of fibrates in the United States and Canada. JAMA. 2011;305:1217–24.

    CAS  PubMed Central  PubMed  Google Scholar 

  76. Downing NS, Ross JS, Jackevicius CA, Krumholz HM. Avoidance of generic competition by Abbott Laboratories’ fenofibrate franchise. Arch Intern Med. 2012;172:724–30.

    PubMed Central  PubMed  Google Scholar 

  77. Brown WV, Ansell BJ, Mackey RH. JCL roundtable: HDL in the primary care setting. J Clin Lipidol. 2014;8:364–72.

    PubMed  Google Scholar 

  78. Sprecher DL. Targeting triglycerides as prognostic indicators and determining lowest values for patient benefit. Curr Cardiol Rep. 2001;3:424–32.

    CAS  PubMed  Google Scholar 

  79. Le NA, Walter MF. The role of hypertriglyceridemia in atherosclerosis. Curr Atheroscler Rep. 2007;9:110–5.

    CAS  PubMed  Google Scholar 

  80. Havel RJ. Triglyceride-rich lipoproteins and plasma lipid transport. Arterioscler Thromb Vasc Biol. 2010;30:9–19.

    CAS  PubMed  Google Scholar 

  81. Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep. 2011;13:544–52.

    PubMed Central  PubMed  Google Scholar 

  82. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, for the European Atherosclerosis Society Consensus Panel, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345–61.

    CAS  PubMed Central  PubMed  Google Scholar 

  83. Kholi P, Cannon CP. Triglycerides: how much credit do they deserve? Med Clin N Am. 2012;96:39–55.

    Google Scholar 

  84. Berglund L, Sacks F, Brunzell JD. Renewed interest in triglycerides. Clin Lipidol. 2013;8:1–4.

    CAS  Google Scholar 

  85. Libby P. Fat fuels the flame: triglyceride-rich lipoproteins and arterial inflammation. Circ Res. 2007;100:299–301.

    CAS  PubMed  Google Scholar 

  86. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 1998;97:1029–36.

    CAS  PubMed  Google Scholar 

  87. Li XL, Hong LF, Luo SH, Guo YL, Zhu CG, Sun J, et al. Impact of admission triglyceride for early outcome in diabetic patients with stable coronary artery disease. Lipids Health Dis. 2014;13:73.

    PubMed Central  PubMed  Google Scholar 

  88. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E, PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE-IT TIMI 22 trial. J Am Coll Cardiol. 2008;51:724–30.

    CAS  PubMed  Google Scholar 

  89. Faergeman O, Holme I, Fayyad R, Bhatia S, Grundy SM, Kastelein JJ, Steering Committees of IDEAL and TNT Trials, et al. Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease. Am J Cardiol. 2009;104:459–63.

    CAS  PubMed  Google Scholar 

  90. Schwartz GG, Abt M, Bao W, DeMicco D, Kallend, M et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015;65:2267–75.

    CAS  PubMed  Google Scholar 

  91. Stauffer ME, Weisenfluh L, Morrison A. Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence. Vasc Health Risk Manag. 2013;9:671–80.

    PubMed Central  PubMed  Google Scholar 

  92. Rader DJ. Spotlight on HDL biology: new insights in metabolism, function, and translation. Cardiovasc Res. 2014;103(3):337–40.

    CAS  PubMed  Google Scholar 

  93. Jørgensen A, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32–41.

    PubMed  Google Scholar 

  94. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384:626–35.

    CAS  PubMed  Google Scholar 

  95. ISIS Pharmaceuticals. ISIS-APOCIIIRx. http://isispharm.com/Pipeline/Therapeutic-Areas/SevereandRare.htm#ISIS-APOCIIIRx. Accessed 20 Sep 2014.

  96. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on the Kidney in Cardiovascular Disease, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292–333.

    PubMed  Google Scholar 

  97. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–39.

    PubMed  Google Scholar 

  98. Expert Dyslipidemia Panel of the International Atherosclerosis Society. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia—full report. J Clin Lipid. 2014;8:29–60.

    Google Scholar 

  99. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, for the European Atherosclerosis Society Consensus Panel, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345–61.

    CAS  PubMed Central  PubMed  Google Scholar 

  100. Reiner Z, Catapano AL, DeBacker G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–818.

    PubMed  Google Scholar 

  101. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2969–89.

    CAS  PubMed Central  PubMed  Google Scholar 

  102. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1—executive summary. J Clin Lipidol. 2014;8:473–88.

    PubMed  Google Scholar 

  103. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–45.

    PubMed  Google Scholar 

  104. Perk J, DeBacker G, Gohlke H, GrahamI Reiner Z, Verschuren M, et al. European guidelines on cardiovascular disease prevention in clinical practice (version, 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;2012(33):1635–701.

    Google Scholar 

  105. Rabinowitch IM. Clinical and other observations on Canadian Eskimos in the Eastern Arctic. Canadian Med Assoc J. 1936;35(5):487–501.

    Google Scholar 

  106. Rudkowska I, Guénard F, Julien P, Couture P, Lemieux S, Barbier O, et al. Genome-wide association study of the plasma triglyceride response to an n-3 polyunsaturated fatty acid (PUFA) supplementation. J Lipid Res. 2014;55:1245–53.

    CAS  PubMed Central  PubMed  Google Scholar 

  107. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens. 2002;20:1493–9.

    CAS  PubMed  Google Scholar 

  108. Lee JH, O’Keefe JH, Lavie CJ, Harris WS. Omega-3 fatty acids: cardiovascular benefits, sources and sustainability. Nat Rev Cardiol. 2009;6:753–8.

    CAS  PubMed  Google Scholar 

  109. Kromhout D, de Goode J. Update on cardiometabolic health effects of ω-3 fatty acids. Curr Opin Lipidol. 2014;25:85–90.

    CAS  PubMed  Google Scholar 

  110. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002;346:1113–8.

    CAS  PubMed  Google Scholar 

  111. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease—effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58:2047–67.

    CAS  PubMed  Google Scholar 

  112. von Schacky C. Omega-3 fatty acids: anti-arrythmic, proarrhythmic, or both? Front Cardiac Electrophysiol. 2012;3:98.

    Google Scholar 

  113. Kang JX, Leaf A. Antiarrhythmic effects of polyunsaturated fatty acids. Circulation. 1996;94:1774–80.

    CAS  PubMed  Google Scholar 

  114. Mozaffarian D, Lemaitre RN, King IB, Song X, Spiegalman D, Sacks FM, et al. Circulating ω-3 fatty acids and incidence of congestive heart failure in older adults: the cardiovascular health study: a cohort study. Ann Intern Med. 2011;155:160–70.

    PubMed Central  PubMed  Google Scholar 

  115. Scorletti E, Byrne CD. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu Rev Nutr. 2013;33:231–48.

    CAS  PubMed  Google Scholar 

  116. Poudyal H, Panchal SK, Diwan V, Brown L. Omega-3 fatty acids and metabolic syndrome: effects and emerging mechanisms of action. Progr Lipid Res. 2011;50:372–87.

    CAS  Google Scholar 

  117. Delmastro-Greenwood M, Freeman BA, Wendell SG. Redox-dependent anti-inflammatory signaling actions of unsaturated fatty acids. Annu Rev Physiol. 2014;76:79–105.

    CAS  PubMed Central  PubMed  Google Scholar 

  118. Adkins Y, Kelley DS. Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. J Nutr Biochem. 2010;21:781–92.

    CAS  PubMed  Google Scholar 

  119. Sala-Vila A, Cofan M, Mateo-Gallego R, Cenarro A, Civeira F, Ros E. Eicosapentaenoic acid in serum phospholipids relates to a less atherogenic lipoprotein profile in subjects with familial hypercholesterolemia. J Nutr Biochem. 2013;24:1604–8.

    CAS  PubMed  Google Scholar 

  120. Rudkowska I. Fish oils for cardiovascular disease: impact on diabetes. Maturitas. 2010;67:25–8.

    CAS  PubMed  Google Scholar 

  121. Merino J, Sala-Vila A, Kones R, Ferre R, Plana N, Girona J, et al. Increasing long-chain n-3 PUFA consumption improves small peripheral artery function in patients at intermediate-high cardiovascular risk. J Nutr Biochem. 2014;25:642–6.

    CAS  PubMed  Google Scholar 

  122. Kones R. Inflammation, CRP, and cardiometabolic risk: how compelling is the potential therapeutic role of omega-3 PUFA in cardiovascular disease? Clin Lipidol. 2011;6:627–30.

    CAS  Google Scholar 

  123. Simopoulos AP. Omega-6/omega-3 essential fatty acid ratio and chronic diseases. Food Res Int. 2004;20:77–90.

    CAS  Google Scholar 

  124. Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood). 2008;233:674–88.

    CAS  Google Scholar 

  125. Schaebel LH, Vertergaard H, Laurberg P, Rathcke CN, Andersen S. Intake of traditional Inuit diet vary in parallel with inflammation as estimated from YKL-40 and hsCRP in Inuit and non-Inuit in Greenland. Atherosclerosis. 2013;228:496–501.

    CAS  PubMed  Google Scholar 

  126. GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999;354:447–455.

  127. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, GISSI-Prevenzione Investigators, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105:1897–903.

    CAS  PubMed  Google Scholar 

  128. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Japan EPA lipid intervention study (JELIS) Investigators, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis [erratum. In: Lancet. 2007;370:220]. Lancet. 2007;369:1090–8.

    CAS  PubMed  Google Scholar 

  129. Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Moshiri M. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival. Cardiovasc Drugs Ther. 1997;11:485–91.

    CAS  PubMed  Google Scholar 

  130. Svensson M, Schmidt EB, Jørgensen KA, Christensen JH, OPACH Study Group. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol. 2006;1:780–6.

    CAS  PubMed  Google Scholar 

  131. von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;130:554–62.

    Google Scholar 

  132. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens. 2002;20:1493–9.

    CAS  PubMed  Google Scholar 

  133. Schiano V, Laurenzano E, Brevetti G, Schiano V, Laurenzano E, Brevetti G. Omega-3 polyunsaturated fatty acid in peripheral arterial disease: effect on lipid pattern, disease severity, inflammation profile, and endothelial function. Clin Nutr. 2008;27:241–7.

    CAS  PubMed  Google Scholar 

  134. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;2:757–61.

    CAS  PubMed  Google Scholar 

  135. Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol. 2009;32:365–72.

    PubMed  Google Scholar 

  136. León H, Shibata MC, Sivakumaran S, Dorgan M, Chatterley T, Tsuyuki RT. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ. 2008;337:a2931.

    PubMed Central  PubMed  Google Scholar 

  137. Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2002;112:298–304.

    CAS  PubMed  Google Scholar 

  138. Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309–18.

    CAS  PubMed  Google Scholar 

  139. Kwak SM, Myung SK, Lee YJ, Seo HG. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med. 2012;172:686–94.

    CAS  PubMed  Google Scholar 

  140. The Risk and Prevention Study Collaborative Group. N-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368:1800–8.

    Google Scholar 

  141. Sekikawa A, Miura K, Lee S, Fujiyoshi A, Edmundowicz D, Kadowaki T, ERA JUMP Study Group, et al. Long-chain n-3 polyunsaturated fatty acids and incidence rate of coronary artery calcification in Japanese in Japan and United states whites—population-based prospective cohort study. Heart. 2014;100:569–73.

    CAS  PubMed Central  PubMed  Google Scholar 

  142. Wu JHY, Mozaffarian D. ω-3 fatty acids, atherosclerosis progression and cardiovascular outcomes in recent trials: new pieces in a complex puzzle. Heart. 2014;100:530–533.

  143. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308:1024–33.

    CAS  PubMed  Google Scholar 

  144. Teva launches first generic of GSK’s Lovaza in US, April 9, 2014. http://www.pmlive.com/pharma_news/teva_launches_first_generic_of_gsks_lovaza_in_us_559273. Accessed 15 Feb 2015.

  145. Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, et al. JELIS. The change in low-density lipoprotein cholesterol concentration is positively related to plasma docosahexaenoic acid but not eicosapentaenoic acid. J Atheroscler Thromb. 2012;19:673–9.

    CAS  PubMed  Google Scholar 

  146. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, placebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial). Am J Cardiol. 2011;108:682–90.

    CAS  PubMed  Google Scholar 

  147. Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). J Clin Lipidol. 2012;6:565–72.

    PubMed  Google Scholar 

  148. Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR Studies. Am J Cardiovasc Drugs. 2013;13:37–46.

    CAS  PubMed Central  PubMed  Google Scholar 

  149. Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110:984–92.

    CAS  PubMed  Google Scholar 

  150. Herper M. Why amarin has to finish its big fish oil study. http://www.forbes.com/sites/matthewherper/2013/10/21/why-it-would-be-morally-wrong-for-amarin-to-stop-its-big-trial-of-heart-drug-vascepa/. Accessed 20 Sep 2014.

  151. Husten L. Amarin says it will complete cardiovascular outcomes trial for its fish oil pill. http://www.forbes.com/sites/larryhusten/2014/09/16/amarin-says-it-will-complete-cardiovascular-outcomes-trial-for-its-fish-oil-pill/. Accessed 10 Mar 2015.

  152. NICE. MI—secondary prevention. Secondary prevention in primary and secondary care for patients following a myocardial infarction National Institute for Health and Care Excellence (NICE) Clinical Guidelines CG172, November, 2013. http://www.nice.org.uk/guidance/cg172/resources/guidance-mi-secondary-prevention-pdf. Accessed 15 Feb 2015.

  153. NICE. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE Clinical Guideline CG181, July 2014. http://www.nice.org.uk/guidance/cg181/resources/guidance-lipid-modification-cardiovascular-risk-assessment-and-the-modification-of-blood-lipids-for-the-primary-and-secondary-prevention-of-cardiovascular-disease-pdf. Accessed 15 Feb 2015.

  154. Omega-3 fatty acid supplements, Nice Advisory KTT4, January 15, 2015. https://www.nice.org.uk/advice/ktt4. Accessed 24 June 2015.

  155. Kastelein JJ, Maki KC, Susekov A, Ezhov M, Nordestgaard BG, Machielse BN, et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol. 2014;8:94–106.

    PubMed  Google Scholar 

  156. Offman E, Marenco T, Ferber S, Johnson J, Kling D, Curcio D, et al. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study. Vasc Health Risk Manag. 2013;9:563–73.

    PubMed Central  PubMed  Google Scholar 

  157. Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, et al. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther. 2013;35:1400–11.

    CAS  PubMed  Google Scholar 

  158. de Lorgeril M, Salen P, Defaye P, Rabaeus M. Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3? BMC Med. 2013;11:5.

    PubMed Central  PubMed  Google Scholar 

  159. Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y, et al. Effects of statins on serum n-3 to n-6 polyunsaturated fatty acid ratios in patients with coronary artery disease. J Cardiovasc Pharmacol Ther. 2013;18:320–6.

    CAS  PubMed  Google Scholar 

  160. Jia L, Betters JL, Yu L. Niemann-Pick C1-Like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. Ann Rev Physiol. 2011;73:239–59.

    CAS  Google Scholar 

  161. Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415–427.

  162. Sudhop T, Reber M, Tribble D, Sapre A, Taggart W, Gibbons P, et al. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J Lipid Res. 2009;50:2117–23.

    CAS  PubMed Central  PubMed  Google Scholar 

  163. Pandor A, Ara RM, Tumur I, Wilkinson AJ, Paisley S, Duenas A, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med. 2009;265:568–80.

    CAS  PubMed  Google Scholar 

  164. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, ENHANCE Investigators, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431–43.

    CAS  PubMed  Google Scholar 

  165. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, SEAS Investigators, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–56.

    PubMed  Google Scholar 

  166. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, SHARP Investigators, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.

    CAS  PubMed Central  PubMed  Google Scholar 

  167. Brown G, Taylor AJ. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med. 2008;358:1504–7.

    CAS  PubMed  Google Scholar 

  168. Drazen JM, Jarcho JA, Morrissey S, Curfman GD. Cholesterol lowering and ezetimibe. N Engl J Med. 2008;358:1507–8.

    CAS  PubMed  Google Scholar 

  169. Jackevicius CA, Tu JV, Ross JS, Ko DT, Krumholz HM. Use of ezetimibe in the United States and Canada. N Engl J Med. 2008;358:1819–28.

    CAS  PubMed  Google Scholar 

  170. Krumholz HM. Emphasizing the burden of proof: the American College of Cardiology 2008 Expert Panel comments on the ENHANCE trial. Circ Cardiovasc Qual Outcomes. 2010;3:565–7.

    PubMed  Google Scholar 

  171. Institute of Medicine of the National Academies (Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease). Evaluation of biomarkers and surrogate endpoints in chronic disease. Washington, DC: Institute of Medicine; 2010.

  172. Lu L, Krumholz HM, Tu JV, Ross JS, Ko DT, Jackevicius CA. Impact of drug policy on regional trends in ezetimibe use. Circ Cardiovasc Qual Outcomes. 2014;7:589–96.

    PubMed Central  PubMed  Google Scholar 

  173. Ross JS, Frazee SG, Garavaglia SB, Levin R, Novshadian H, Jackevicius CA, et al. Trends in use of ezetimibe after the ENHANCE trial, 2007 through 2010. JAMA Intern Med. 2014;174:1486–93.

    PubMed  Google Scholar 

  174. Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008;156:826–32.

    CAS  PubMed  Google Scholar 

  175. Farnier M, Guyton JR, Jensen E, Polis AB, Johnson-Levonas AO, Brudi P. Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia. Atherosclerosis. 2013;229:415–22.

    CAS  PubMed  Google Scholar 

  176. Laufs U, Descamps OS, Catapano AL, Packard CJ. Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention. Eur Heart J. 2014;35:1996–2000.

    PubMed  Google Scholar 

  177. Cannon CP. IMPROVE-IT trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. American Heart Association 2014 Scientific Sessions; November 17, 2014; Chicago, IL. [late breaking abstract session LBCT.02]. http://www.abstractsonline.com/pp8/#!/3547/presentation/49570. Accessed 20 Feb 2015.

  178. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Therouxet P, et al. For the IMPROVE-IT investigators. Ezetimibe added to statin therapy after acute coronary syndromes. New Engl J Med. 2015;372:2387–97.

  179. Myocardial Infarction Genetics Consortium Investigators. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014;371:2072–82.

    Google Scholar 

  180. Ference BA, Flack JM. Effect of naturally random allocation to lower LDL-C mediated by polymorphisms in NPC1L1, HMGCR or both on the risk of coronary heart disease: a 2×2 factorial Mendelian randomization study [poster no. 2258]. Chicago: American Heart Association Scientific Sessions 2014; 15–19 Nov 2014.

  181. Gudzune KA, Monroe AK, Sharma R, Ranasinghe PD, Chelladurai Y, Robinson KA. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy. A systematic review: effectiveness of combination therapy with statin. Ann Intern Med. 2014;160:468–76.

    PubMed  Google Scholar 

  182. Zhao YT, Chen Q, Sun YX, Li XB, Zhang P, Xu Y, et al. Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary artery disease: a meta-analysis of randomized controlled trials. Ann Med. 2009;41:301–10.

    PubMed  Google Scholar 

  183. von Schacky C. Omega-3 fatty acids in cardiovascular disease—an uphill battle. Prostaglandins Leukot Essent Fatty Acids. 2015;92:41–7.

    Google Scholar 

  184. Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther. 2013;35:1082–98.

    CAS  PubMed  Google Scholar 

  185. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–72.

    CAS  PubMed  Google Scholar 

  186. Bjørklund MM, Hollensen AK, Hagensen MK, Dagnæs-Hansen F, Christoffersen C, Mikkelsen JG, et al. Induction of atherosclerosis in mice and hamsters without germline genetic engineering. Circ Res. 2014;114:1684–9.

    PubMed  Google Scholar 

  187. Alborn WE, Cao G, Careskey HE, Qian YW, Subramaniam DR, Davies J, et al. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem. 2007;53:1814–9.

    CAS  PubMed  Google Scholar 

  188. Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol. 2014;11:563–75.

    CAS  PubMed  Google Scholar 

  189. Ridker PM. LDL cholesterol: controversies and future therapeutic directions. Lancet. 2014;384:607–17.

    CAS  PubMed  Google Scholar 

  190. Stein EA, Swergold GD. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics. Curr Atheroscler Rep. 2013;15:310.

    PubMed  Google Scholar 

  191. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, for the The DESCARTES Investigators, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370:1809–19.

    CAS  PubMed  Google Scholar 

  192. Raal FJ, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, et al. The addition of evolocumab (AMG 145) allows the majority of familial hypercholesterolemic patients to achieve low-density lipoprotein cholesterol goals: results from the phase 3 randomized, double-blind placebo-controlled study [abstract no. 5037]. Washington, DC: American College of Scientific Sessions 2014; 29 Mar 2014.

  193. Cho L, Rocco M, Colquhoun D, Rosenson RS, Dent R, Zue A, et al. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. Clin Cardiol. 2014;37:131–9.

    PubMed  Google Scholar 

  194. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, et al. GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2541–8.

    CAS  PubMed  Google Scholar 

  195. Amgen. Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) [ClinicalTrials.gov. identifier NCT01764633]. Bethesda: US National Institutes of Health. http://clinicaltrials.gov/show/NCT01764633. Accessed 20 Sep 2014.

  196. Roth EM, Taskinen M, Ginsberg H, et al. A 24-week study of alirocumab as monotherapy versus ezetimibe: the first Phase 3 data of a proprotein convertase subtilisin/kexin type 9 inhibitor. J Am Coll Cardiol. 2014;63(12_S).

  197. Farnier M, Kastelein JJP, Roth E, Taskinen MR, Ginsberg HN, Colhoun HM, et al. Relationship between alirocumab, PCSK9 and LDL-C levels: results from the ODYSSEY MONO Phase 3 trial of alirocumab 75 mg every 2 weeks [abstract no. EAS-0758]. Madrid: EAS; 31 May–3 Jun 2014.

  198. Sanofi. Phase III study to evaluate alirocumab in patients with hypercholesterolemia not treated with a statin (ODYSSEY CHOICE II) [ClinicalTrials.gov. identifier NCT02023879]. Bethesda: US National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT02023879. Accessed 10 Mar 2015.

  199. Sanofi. Long-term safety and tolerability of alirocumab SAR236553 (REGN727) versus placebo on top of lipid-modifying therapy in high cardiovascular risk patients with hypercholesterolemia (ODYSSEY Long Term) [ClinicalTrials.gov. identifier NCT01507831]. Bethesda: US National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT01507831. Accessed 10 Mar 2015.

  200. Cholesterol drug halves heart attack and stroke in early test. The N. Y. Times via Reuters. August 31, 2014. http://www.nytimes.com/2014/09/01/business/international/cholesterol-drug-halves-heart-attack-and-stroke-in-early-test.html. Accessed 19 Mar 2015.

  201. Sanofi. The efficacy and safety of alirocumab SAR236553 (REGN727) versus ezetimibe on top of statin in high cardiovascular risk patients with hypercholesterolemia (ODYSSEY Combo II) [ClinicalTrials.gov. identifier NCT01644188]. Bethesda: US National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT01644188. Accessed 10 Mar 2015.

  202. Sanofi. ODYSSEY Outcomes: evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab SAR236553 (REGN727). [ClinicalTrials.gov. identifier NCT01644188]. Bethesda: US National Institutes of Health. http://clinicaltrials.gov/show/NCT01663402. Accessed 10 Mar 2015.

  203. Moriarty PM, Jacobson TA, Bruckert E, Thompson PD, Guyton JR, Baccara-Dinet MT, et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol. 2014;8:554–61.

    PubMed  Google Scholar 

  204. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, et al. ODYSSEY ALTERNATIVE: efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and satin rechallenge arm. Late-Breaking Clinical Trial Abstracts. Circulation. 2014;2(130):2108–9.

    Google Scholar 

  205. Ballantyne CM, Neutel J, Cropp A, Duggan W, Wang E, Plowchalk D, et al. Efficacy and safety of bococizumab (RN316/PF-04950615), a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 in statin-treated hypercholesterolemic subjects: results from a randomized, placebo-controlled, dose-ranging study (NCT: 01592240) [abstract no. 1183-129]. Washington, DC: American College of Cardiology Scientific Session, 29–31 Mar 2014.

  206. Pfizer. The evaluation of PF-04950615 (RN316), in reducing the occurrence of major cardiovascular events in high risk subjects (SPIRE-1) [ClinicalTrials.gov. identifier NCT01975376]. Bethesda: US National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT01975376. Accessed 10 Mar 2015.

  207. Pfizer. The evaluation of PF-04950615 (RN316) in reducing the occurrence of major cardiovascular events in high risk subjects (SPIRE-2) [ClinicalTrials.gov. identifier NCT01975389]. Bethesda: US National Institutes of Health. https://clinicaltrials.gov/ct2/show/results/NCT01975389. Accessed 10 Mar 2015.

  208. Sheridan C. Phase 3 data for PCSK9 inhibitor wows. Nat Biotech. 2013;31:1057–8.

    CAS  Google Scholar 

  209. Beasley D. FDA probes cognitive impact of new cholesterol drugs. March 7, 2014. http://www.reuters.com/article/2014/03/07/us-regeneron-cholesterol-idUSBREA261KU20140307. Accessed 19 Mar 2015.

  210. Norata GD, Tibolla G, Catapano AL. PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges. Vascul Pharmacol. 2014;62:103–11.

    CAS  PubMed  Google Scholar 

  211. Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9. A key modulator of cardiovascular health. Circ Res. 2014;114:1022–36.

    CAS  PubMed  Google Scholar 

  212. Shapiro MD, Fazio S, Tavori H. Targeting PCSK9 for therapeutic gains. Curr Atheroscler Rep. 2015;17:499.

    PubMed  Google Scholar 

  213. Rader DJ, Kastelein JJP. Lomitapide and mipomersen. Two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014;129:1022–32.

    PubMed  Google Scholar 

  214. Wong E, Goldberg T. Mipomersen (Kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia. PT. 2014;39:119–22.

    Google Scholar 

  215. Bell DA, Hooper AJ, Watts GF, Burnett JR. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. Vasc Health Risk Manag. 2012;8:651–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  216. Crooke ST, Geary RS. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol. 2013;76:269–76.

    CAS  PubMed Central  PubMed  Google Scholar 

  217. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998–1006.

    CAS  PubMed  Google Scholar 

  218. Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, Chin W, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012;126:2283–92.

    CAS  PubMed  Google Scholar 

  219. McGowan MP, Tardif JC, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One. 2012;7:e49006.

    CAS  PubMed Central  PubMed  Google Scholar 

  220. Santos RD, Raal FJ, Catapano AL, Witztum JL, Steinhagen-Thiessen E, Tsimikas S. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015;35:689–99.

    CAS  PubMed  Google Scholar 

  221. Kynamro (mipomersen sodium) injection solution for subcutaneous injection [prescribing information]. Cambridge: Genzyme Corp.; 2013. http://www.kynamro.com/~/media/Kynamro/Files/kynamro-pi.pdf. Accessed 26 Feb 2015.

  222. Wong E, Goldberg T. Mipomersen (kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia. P T. 2014;39:119–22.

    PubMed Central  PubMed  Google Scholar 

  223. deGoma EM. Lomitapide for the management of homozygous familial hypercholesterolemia. Rev Cardiovasc Med. 2014;15:109–118.

  224. Raal FJ. Lomitapide for homozygous familial hypercholesterolaemia. Lancet. 2013;381:7–8.

    PubMed  Google Scholar 

  225. Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356:148–56.

    CAS  PubMed  Google Scholar 

  226. Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Phase 3 HoFH Lomitapide Study Investigators, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40–6.

    CAS  PubMed  Google Scholar 

  227. Cuchel M, Blom D, Averna MR, Meagher EA, Theron HD, Sirtori CR, et al. Sustained LDL-C lowering and stable hepatic fat levels in patients with homozygous familial hypercholesterolemia treated with the microsomal triglyceride transfer protein inhibitor, lomitapide: results of an ongoing long-term extension study. Circulation. 2013;128:A16516.

    Google Scholar 

  228. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998–1006.

    CAS  PubMed  Google Scholar 

  229. Kones R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther. 2011;5:325–380.

  230. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317–25.

    CAS  PubMed  Google Scholar 

  231. Rohla M, Weiss TW. Adipose tissue, inflammation and atherosclerosis. Clin Lipidol. 2014;9:71–81.

    CAS  Google Scholar 

  232. Tsiantoulas D, Diehl CJ, Witztum JL, Binder CJ. B Cells and humoral immunity in atherosclerosis. Circ Res. 2014;114:1743–56.

    CAS  PubMed Central  PubMed  Google Scholar 

  233. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:19–46.

    Google Scholar 

  234. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science. 2013;339:161–6.

    CAS  PubMed Central  PubMed  Google Scholar 

  235. Ghattas A, Griffiths HR, Devitt A, Lip GYH, Shantsila E. Monocytes in coronary artery disease and atherosclerosis. Where are we now? J Am Coll Cardiol. 2013;62:1541–51.

    CAS  PubMed  Google Scholar 

  236. Witztum JL, Lichtman AH. The influence of innate and adaptive immune responses on atherosclerosis. Annu Rev Pathol Mech Dis. 2014;9:73–102.

    CAS  Google Scholar 

  237. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.

    CAS  PubMed  Google Scholar 

  238. Giunzioni I, Bonomo A, Bishop E, Castiglioni S, Corsini A, Bellosta S. Cigarette smoke condensate affects monocyte interaction with endothelium. Atherosclerosis. 2014;234:383–90.

    CAS  PubMed  Google Scholar 

  239. Nordestgaard BG, Palmer TM, Benn M, Zacho J, Tybjærg-Hansen A, et al. The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a mendelian randomisation approach. PLoS Med. 2012;9:e1001212.

    PubMed Central  PubMed  Google Scholar 

  240. Thomsen M, Nordestgaard BG. Myocardial infarction and ischemic heart disease in overweight and obesity with and without metabolic syndrome. JAMA Intern Med. 2014;174:15–22.

    CAS  PubMed  Google Scholar 

  241. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299–308.

    CAS  PubMed  Google Scholar 

  242. Jørgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjarg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013;34:1826–33.

    PubMed  Google Scholar 

  243. Varbo A, Benn M, Tybjarg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013;128:1298–309.

    CAS  PubMed  Google Scholar 

  244. Benn M, Tybjaerg-Hansen A, McCarthy MI, Jensen GB, Grande P, Nordestgaard BG. Nonfasting glucose, ischemic heart disease, and myocardial infarction: a Mendelian randomization study. J Am Coll Cardiol. 2012;19(59):2356–65.

    Google Scholar 

  245. Kones R. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag. 2013;9:617–70.

    PubMed Central  PubMed  Google Scholar 

  246. Arbab-Zadeh A, Nakano M, Virmani R, Fuster V. Acute coronary events. Circulation. 2012;125:1147–56.

    PubMed Central  PubMed  Google Scholar 

  247. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol. 2010;30:1282–92.

    CAS  PubMed  Google Scholar 

  248. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368:2004–13.

    CAS  PubMed  Google Scholar 

  249. Libby P, Tabas I, Fredman G, Fisher EA. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res. 2014;114:1867–79.

    CAS  PubMed Central  PubMed  Google Scholar 

  250. Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science. 2013;11(339):166–72.

    Google Scholar 

  251. Fredman G, Ozcan L, Tabas I. Common therapeutic targets in cardiometabolic disease. Science Transl Med. 2014;6:1–5.

    Google Scholar 

  252. Dinarello CA. A clinical perspective of interleukin-1β as the gatekeeper of inflammation. Eur J Immunol. 2011;41:1203–17.

    CAS  PubMed  Google Scholar 

  253. Kones R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease—a perspective. Drug Des Devel Ther. 2010;4:383–413.

    CAS  PubMed Central  PubMed  Google Scholar 

  254. Satoh K, Shimokawa H. High-sensitivity C-reactive protein: still need for next-generation biomarkers for remote future cardiovascular events. Eur Heart J. 2014;35:1776–8.

    PubMed  Google Scholar 

  255. Braunwald E. Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials. Eur Heart J. 2012;33:430–2.

    PubMed  Google Scholar 

  256. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132–40.

    PubMed  Google Scholar 

  257. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145:21–9.

    CAS  PubMed  Google Scholar 

  258. Wilson PW, Pencina M, Jacques P, Selhub J, D’Agostino R Sr, O’Donnell CJ. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes. 2008;1:92–7.

    PubMed Central  PubMed  Google Scholar 

  259. Kaptoge S, Seshasai SR, Gao P, Freitag DF, Butterworth AS, Borglykke A, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2014;35:578–89.

    CAS  PubMed Central  PubMed  Google Scholar 

  260. Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet. 2012;379:1214–24.

    Google Scholar 

  261. IL6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379:1205–13.

    PubMed Central  Google Scholar 

  262. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJP, for the JUPITER Study Group JUPITER Study Group, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.

    CAS  PubMed  Google Scholar 

  263. Henao-Mejia J, Elinav E, Thaiss CA, Flavell RA. Inflammasomes and metabolic disease. Annu Rev Physiol. 2014;76:57–78.

    CAS  PubMed  Google Scholar 

  264. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357–61.

    CAS  PubMed Central  PubMed  Google Scholar 

  265. Imazio M, Brucato A, Ferrazzi P, Pullara A, Adler Y, Barosi A, for the COPPS-2 Investigators, et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA. 2014;312:1016–23.

    CAS  PubMed  Google Scholar 

  266. Nidorf SM, Eikelboom JW, Thompson PL. Colchicine for secondary prevention of cardiovascular disease. Curr Atheroscler Rep. 2014;16:391.

    PubMed  Google Scholar 

  267. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1b inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597–605.

    CAS  PubMed  Google Scholar 

  268. Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, on behalf of the CANTOS Pilot Investigative Group, et al. Effects of interleukin-1 inhibition with canakinumab on hemoglobin A1c, lipids, C-eactive protein, interleukin-6, and fibrinogen. A phase IIb randomized, placebo-controlled trial. Circulation. 2012;126:2739–48.

    CAS  PubMed  Google Scholar 

  269. Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014;35:1782–91.

    CAS  PubMed Central  PubMed  Google Scholar 

  270. Ridker PM. Targeting inflammatory pathways for the treatment of cardiovascular disease. Eur Heart J. 2014;35:540–3.

    PubMed Central  PubMed  Google Scholar 

  271. Everett BM, Pradhan A, Solomon DH, Paynter N, MacFadyen J, Zaharris E, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013;166(199–207):e15.

    PubMed  Google Scholar 

  272. Ridker P. Cardiovascular Inflammation Reduction Trial (CIRT) [Clinicaltrials.gov identifier NCT01594333]. Bethesda: US National Institutes of Health. http://clinicaltrials.gov/show/NCT01594333. Accessed 24 June 2015.

  273. Pagnoux C, Goulet M. Role and place of methotrexate in vasculitis management. Int J Clin Rheumtol. 2009;4:697–715.

    CAS  Google Scholar 

  274. Olbetam capsules 250. SPC. http://www.medicines.org.uk/emc/medicine/5355. Accessed 24 Sep 2014.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Richard Kones.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare.

Funding

No external funding was used for this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kones, R., Rumana, U. Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs. Drugs 75, 1201–1228 (2015). https://doi.org/10.1007/s40265-015-0429-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0429-3

Keywords

Navigation